EF Hutton has initiated coverage on shares of Biomea Fusion Inc. (NASDAQ: BMEA) with a Buy rating and set a price target of $128.00.
The firm's analysis is based on the potential of Biomea Fusion's BMF-219, which is currently in early-stage trials for the treatment of diabetes.
The analyst from EF Hutton has applied a conservative Probability of Success factor of 10% to BMF-219 due to its current phase 1/2 development status and the vast size of the diabetes market. This factor reflects the early stage of the drug's development and the inherent uncertainties at this phase.
In addition to the Probability of Success factor, EF Hutton has incorporated a 30% discount rate into their valuation models. This rate is used to adjust the projected cash flows from BMF-219 to their present value, considering the risks associated with the drug's development timeline.
The firm also anticipates that Biomea Fusion will raise additional capital, which has been factored into the final share count projections. These projections contribute to the firm's valuation methods, which include Free Cash Flow to the firm (FCFF), discounted EPS (dEPS), and sum-of-the-parts (SOP) models.
The price target of $128.00 is derived from an equal-weighted average of these models, rounded to the nearest whole number. This target represents EF Hutton's valuation for Biomea Fusion over a 12-month period.
In other recent news, Biomea Fusion has made significant strides with its BMF-219 studies after the U.S. Food and Drug Administration (FDA) lifted the clinical hold on these trials. The company is currently conducting Phase I/II and Phase II clinical trials, evaluating the safety and efficacy of BMF-219 in patients with type 1 and type 2 diabetes.
The decision by the FDA was followed by several analyst firms adjusting their stance on the company. Piper Sandler reaffirmed its Overweight rating, while Scotiabank and H.C. Wainwright raised their price targets. Truist Securities upgraded the company's stock from Hold to Buy.
The company is also expected to release preclinical safety and efficacy data for a new obesity drug candidate. These recent developments have prompted positive responses from various analyst firms. Scotiabank, H.C. Wainwright, and Truist Securities have all expressed confidence in the drug's potential and look forward to the forthcoming Phase 2b data readout, expected by the end of 2024.
Additionally, Biomea Fusion recently announced the formation of its Global Scientific Advisory Board, comprising international experts in diabetes and beta cell science. The board will guide the development of BMF-219, aiming to improve the health of insulin-producing beta cells.
InvestingPro Insights
To complement EF Hutton's analysis of Biomea Fusion Inc. (NASDAQ:BMEA), recent data from InvestingPro offers additional context for investors. Despite the optimistic price target set by EF Hutton, it's important to note that Biomea Fusion is currently not profitable, with a negative operating income of $148.4 million over the last twelve months as of Q2 2023. This aligns with an InvestingPro Tip indicating that analysts do not anticipate the company will be profitable this year.
However, the company's financial position isn't entirely bleak. An InvestingPro Tip highlights that Biomea Fusion holds more cash than debt on its balance sheet, which could be crucial for funding ongoing research and development of BMF-219. This cash position may also explain why EF Hutton anticipates additional capital raising, as mentioned in their analysis.
The stock has shown significant momentum recently, with a strong 65.7% return over the last month and an impressive 142.55% return over the last three months. This recent performance could be reflecting market optimism about the potential of BMF-219, although it's worth noting that another InvestingPro Tip suggests the stock may be in overbought territory based on its RSI.
For investors seeking a more comprehensive analysis, InvestingPro offers 9 additional tips for Biomea Fusion, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.